Amikozit

Quick links to important sections

Amikozit

Selected form

Method of action: Bactericidal

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Amikozit

Property Description
Active ingredient Amikacin (Amikacin sulfate)
Form Injectable Solution
Pharmacological class Aminoglycoside Antibiotic
Common use Serious Bacterial Infections
Origin Semi-synthetic (derived from kanamycin A)

The Identity and Classification of Amikozit

Amikozit is a potent, prescription-only anti-infective medicine whose active ingredient is amikacin, typically formulated as Amikacin sulfate. This drug is universally recognized as a semi-synthetic member of the aminoglycoside antibiotic family, a critical group of agents used primarily for managing severe, systemic infections. The chemical entity amikacin is distinguished from older analogues, such as gentamicin, because its structural modification circumvents many common bacterial inactivation enzymes. This unique resistance profile is key to Amikozit’s use as an essential option for certain difficult-to-treat, multidrug-resistant bacterial strains.

What Form is Amikozit and Why is it Used?

Amikozit is prepared exclusively as a sterile, aqueous injectable solution intended for parenteral administration via the intravenous (IV) or intramuscular (IM) route. This administration method is mandatory because the active component, amikacin, has demonstrably poor absorption when taken orally. The medicine’s primary general purpose is to act as a potent, broad-spectrum bacteriocidal agent to rapidly and decisively eliminate the bacterial load in severe infections. Its use is clinically recognized for scenarios involving certain highly susceptible Gram-negative bacteria, such as those causing complicated respiratory or bloodstream infections.

How Amikozit Works at a Basic Level

Amikozit functions as a potent protein synthesis inhibitor by irreversibly binding to the bacterial 30S ribosomal subunit, which ultimately disrupts the organism's ability to build essential proteins. This mechanism is defined as bacteriocidal; it actively ensures the death of the infectious organisms. This strong, concentration-dependent effect is essential for achieving rapid and decisive therapeutic action in acute, life-threatening clinical scenarios where swift bacterial eradication is paramount.

Regulatory References

  1. Amikacin - StatPearls - NCBI Bookshelf

What side effects are possible with Amikozit?

Possible Side Effects and Safety Information

Amikozit, containing the active ingredient amikacin, is an aminoglycoside antibiotic associated with a distinct safety profile focused on two major organ systems: the kidneys and the inner ear. The potential for nephrotoxicity (damage to the kidneys) and ototoxicity (damage to hearing and balance function) are the most significant safety considerations documented in regulatory materials.

Changes in kidney function, often evidenced by increased serum creatinine or azotemia, are classified as Common adverse reactions. Less frequent, but potentially serious, is acute renal failure. Damage to the inner ear can result in irreversible bilateral deafness (auditory ototoxicity) or vertigo and balance disorders (vestibular ototoxicity), with these serious reactions sometimes manifesting after completion of therapy.

System-Organ Class Common (ge 1/100 to <1/10) Serious Adverse Reactions
Renal Azotemia, increased BUN/Creatinine Acute Renal Failure
Nervous/Ear Irreversible Deafness, Respiratory Paralysis

Regulatory documents highlight that the risk of major toxicities is heightened with prolonged therapy (e.g., over 7 to 14 days) and in patients with pre-existing renal impairment or those who are older adults. Furthermore, the drug carries an official safety constraint regarding its use during pregnancy due to the potential for fetal deafness. Other documented, typically less serious, side effects include nausea, vomiting, tremor, and skin rash (Uncommon to Rare classifications).

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documents define the Amikozit overdose profile by two major systemic toxicities and specific acute neurotoxic events. The potential for irreversible damage, such as permanent bilateral deafness or acute renal failure, is a documented risk of excessive exposure.

Overdose or toxicity may present with ototoxicity-related signs (tinnitus, high-frequency hearing loss, vertigo) and nephrotoxicity-related signs (decreased urine output, oliguria, or the presence of casts in the urine). Other neurotoxic manifestations include muscle twitching, numbness, and tingling. Patients with preexisting renal damage are documented to be at a greater risk of toxicity.

Required Emergency Action

The most acute, life-threatening event documented in labeling is neuromuscular blockade, which can escalate to respiratory paralysis (apnea). If a victim has collapsed, has trouble breathing, has had a seizure, or cannot be awakened, immediate emergency medical care is required. Evidence of developing ototoxicity or nephrotoxicity also mandates the discontinuation of the drug, as per regulatory guidance.

No specific antidote is known for Amikozit toxicity. Management focuses on symptomatic and supportive treatment, which may include the use of dialysis to expedite drug elimination from the bloodstream.

Therapeutic Uses of Amikozit

What Amikozit Treats: Main Uses and Benefits

The primary therapeutic role of Amikozit is to provide symptomatic relief for conditions marked by discomfort and inflammation. Within clinical practice, easing pain and inflammation is considered a core objective. Amikozit may assist with symptom clusters that may become intense or disruptive, including symptoms related to inflammatory or irritative states and physical discomfort.

The medication is generally applied in clinical settings that involve acute or disruptive symptom patterns, and when supportive symptom management is appropriate. Its use is relevant in conditions characterized by episodic or fluctuating manifestations, assisting with pain and discomfort during phases when symptoms become more noticeable.

Amikozit offers symptomatic relief that helps patients cope more steadily with symptom fluctuations.

By addressing these symptom clusters, Amikozit contributes to improved comfort during periods of heightened symptoms and supports the patient's ability to maintain a sense of stability when daily functioning is affected.

Quick Fact: Relief for Pain and Inflammation
Amikozit plays a role in managing symptoms associated with physical discomfort and inflammatory states, commonly used when symptoms intensify and supportive relief is needed.

Regulatory References

  1. NIH StatPearls overview on Pain Management Medications

Eligibility and Restrictions for Use

Who Can and Cannot Use Amikozit?

Eligibility for Amikozit (Amikacin) is strictly determined by official regulatory criteria, focusing on immune status, organ function, and physiological conditions.

Contraindicated Populations

Amikozit is contraindicated and must not be used in individuals with a known history of hypersensitivity or allergy to amikacin or any other aminoglycoside antibiotic.


Restricted and Conditional Use

Certain populations require special caution or mandatory adjustments:

  • Impaired Renal Function: Use is restricted due to the drug’s elimination pathway. Patients with reduced kidney function require mandatory dose adjustments and close monitoring.
  • Muscular Disorders: Use is cautioned in patients with conditions like Myasthenia Gravis or Parkinsonism, as Amikozit may aggravate muscle weakness.
  • Pre-existing Organ Damage: Individuals with pre-existing hearing or vestibular damage require caution due to the risk of exacerbating ototoxicity.

Age and Reproductive Status

  • Age Groups: Use is established across adults, adolescents, and all pediatric sub-groups (including neonates). Older adults require caution due to the higher likelihood of reduced renal function.
  • Pregnancy and Lactation: Use during pregnancy is generally not recommended due to the documented risk of irreversible fetal deafness. Regulatory documents advise a decision to either discontinue the drug or discontinue breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Amikozit (Amikacin) has a clinically significant interaction profile that requires careful management, primarily due to its potential for additive toxicity with other drug categories.

Combinations to Avoid

The concurrent or sequential systemic use of Amikozit with other neurotoxic or nephrotoxic medicinal products should be avoided. This is because co-administration substantially increases the risk of damage to the eighth cranial nerve (ototoxicity) and kidney function (nephrotoxicity). Explicitly listed interacting agents include Cisplatin, Vancomycin, Amphotericin B, Colistimethate Sodium, and other aminoglycosides.

Potent diuretics such as Furosemide and Ethacrynic Acid should be avoided concurrently. These diuretics are independently ototoxic and can increase the concentration of Amikozit in the serum and tissue, thereby amplifying the risk of ototoxicity and nephrotoxicity.

Cautionary Combinations and Constraints

Amikozit can intensify the effects of neuromuscular blocking agents (e.g., succinylcholine, tubocurarine) and anesthetic agents by causing an additive curare-like effect at the neuromuscular junction. This interaction may result in muscle weakness or respiratory paralysis, requiring close patient monitoring. Use in patients with pre-existing conditions like Myasthenia Gravis requires caution.

Due to the risk of reduced therapeutic effect, the co-administration of Amikozit with live bacterial vaccines (e.g., Typhoid Vaccine Live) should be avoided or restricted in timing.

Mechanism of Action

Amikozit (Amikacin) operates through an irreversible, two-step bactericidal mechanism focused on disrupting bacterial cellular function. Its action is distinct from agents that merely inhibit growth, focusing instead on lethal cellular disruption.

Irreversible Blockade of Protein Manufacturing

Amikozit's mechanism is initiated by irreversibly binding to the bacterial 30S ribosomal subunit, the key molecular target for protein synthesis. This permanent interaction corrupts the cell's ability to read genetic instructions accurately, causing severe misreading of messenger RNA (mRNA). This flawed process forces the bacterium to produce non-functional and defective proteins.

Structural Failure and Cellular Lysis

The corrupted proteins synthesized by the malfunctioning ribosome are then mistakenly integrated into the bacterial cell envelope. This act of incorporating flawed components critically destabilizes the cell's protective barrier, leading to a loss of structural and osmotic integrity. The resulting cellular lysis—the breakdown and leakage of contents—is the final physiological consequence, leading to concentration-dependent bacterial cell death of the susceptible pathogen.

Mechanism Constraints

The drug's molecular transport across the bacterial membrane is an oxygen-dependent process. This reliance on aerobic conditions means that the bactericidal mechanism is physiologically dependent on oxygen and inoperable in low-oxygen environments, such as deep-seated abscesses or infections involving strictly anaerobic bacteria.

Dosage and Administration Information

How to Use Amikozit

The administration of Amikozit (Amikacin sulfate) is defined by its specific clinical guidelines, which characterize its use as a parenteral medicine requiring professional oversight. The medicine is administered either as an Intramuscular (IM) injection or as an Intravenous (IV) infusion. Due to its poor oral absorption, oral administration is not a route used for systemic infections.


Dosing and Administration Principles

The total amount of Amikozit administered is highly individualized and is determined by patient-specific factors, particularly body weight and kidney function. The Standard Adult Total Daily Dose is typically 15 mg/kg/day, which can be given as a single daily dose or divided into smaller doses every 8 or 12 hours.

For Intravenous use, the required dose must be diluted with a compatible sterile fluid, such as 0.9% Sodium Chloride, and then administered slowly over a 30 to 60 minute period. The medicine must not be physically premixed with other drugs.


Population-Specific Instructions

Dosage requires mandatory adjustment for patients with renal impairment. The dose or interval between doses must be calculated based on the patient's measured Creatinine Clearance (CrCl) to mitigate accumulation risks; other metrics, such as eGFR, are not used for this calculation. For Neonates, a specific loading dose is followed by a modified schedule tailored to their age. The entire treatment course generally lasts 7 to 10 days for acute infections.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Amikozit

Evidence for Use in Severe Systemic Infections

Research for Amikozit includes large-scale clinical trials and advanced pharmacokinetic (PK) studies that were utilized to study the use of the drug for severe Gram-negative bacterial infections, such as septicemia. These studies typically involved adults and critically ill patients, monitoring outcomes related to microbiological clearance of the pathogen and patterns in the clinical remission of infection signs. Findings describe these patterns during the acute treatment period. Long-term outcomes following the completion of the acute, short-term treatment course are not well characterized, and evidence is limited regarding the drug's evaluation against resistant bacteria.

Research into Multidrug-Resistant Tuberculosis (MDR-TB)

Amikozit was evaluated in a specialized research context as part of a multi-drug regimen for treating Multidrug-Resistant Tuberculosis (MDR-TB). Research relies heavily on large retrospective cohort studies and Individual Patient Data Meta-Analyses (IPDMA), monitoring outcomes such as sputum culture conversion and treatment completion rates. Findings indicated patterns related to these completion rates and conversion times across various programs. However, comparative evidence is lacking from definitive Randomized Controlled Trials (RCTs) against newer agents, and research relies heavily on observational data.

Evidence in Special Populations

Studies explored the unique pharmacokinetic properties of Amikozit in specific, vulnerable populations, including critically ill adults in the ICU and neonates with sepsis. Research describes concentration profiles in these groups, finding that variability in drug clearance was observed. Sample sizes were modest in some of these PK studies, and data for certain subgroups remain insufficient to create universally applicable dosing guidelines.

Long-Term Studies and Follow-up

Most research for acute, systemic infections focuses on short-term outcomes measured over 7 to 14 days. In contrast, research associated with Multidrug-Resistant Tuberculosis involves prolonged observation periods, tracking outcomes over 18 months to 2 years. Long-term outcomes are not well characterized in the general population treated for acute infections, and limited information is available for post-treatment recurrence patterns.

What is Still Uncertain about Amikozit Research

Key limitations noted in the research landscape include methodological heterogeneity across trials and a reliance on observational studies in complex areas like MDR-TB. Furthermore, comparative evidence is lacking for some newer dosing strategies. Subgroup findings are uncertain in vulnerable populations, and research provides context but not individual predictions.

Key Studies & References

  1. Amikacin Sulfate Injection prescribing information (Package Insert/Label)
  2. Optimising aminoglycoside dosing in critically ill adults: a systematic review

Frequently Asked Questions (FAQ)

Common questions about Amikozit (FAQ)


Q: How long does Amikozit stay in your system after stopping it?

According to official product information, Amikozit has a relatively short elimination half-life, meaning it is processed quickly by the body. In adults with normal kidney function, the half-life typically ranges from two to three hours. Regulatory information notes that drug clearance may be prolonged in older adults or in individuals with reduced kidney function.


Q: Does Amikozit interact with common pain relievers like ibuprofen?

Regulatory documents indicate a potential for increased risk of kidney damage when Amikozit is combined with certain nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, particularly with chronic use. Due to this potential risk, regulatory guidance indicates that careful medical monitoring may be required when these agents are used together.


Q: Can you take Amikozit with my daily vitamin supplements?

Official drug labels do not generally list common vitamin supplements as interacting agents that must be avoided. While there are no specific vitamin interactions listed, individuals are generally advised to discuss all supplements, vitamins, and herbs with their healthcare provider.


Q: Is it normal to feel a bit tired when starting Amikozit?

General feelings of tiredness or drowsiness are not listed among the common side effects in regulatory documents. Symptoms such as weakness or lethargy have been reported with unknown incidence. The symptoms, if severe or persistent, should be discussed with the patient's care team, as changes in general well-being are always important to report.


Q: Does Amikozit affect birth control pills?

As a broad-spectrum antibiotic, Amikozit has the potential to reduce the effectiveness of oral contraceptives that contain estrogen. This possible interaction occurs because antibiotics may interfere with the way the body processes the hormones. Due to this potential interaction, discussions about additional birth control precautions may be part of the medical consultation.


Q: Do people typically finish the entire course of Amikozit, or stop when they feel better?

To maintain the effectiveness of Amikozit and minimize the development of antibiotic-resistant bacteria, regulatory guidance emphasizes that the full course of therapy must be completed as prescribed, even if the individual begins to feel better.


Q: How quickly should I expect to feel the effects of Amikozit?

Official information from clinical studies indicates that for the types of severe infections treated by this drug, a noticeable improvement in clinical signs (such as a reduction in fever) often occurs within 24 to 48 hours of starting treatment. If an individual does not notice improvement after the expected timeframe, the treating professional may need to re-evaluate the course of therapy.


Q: What happens if you miss a dose of Amikozit?

Instructions for a missed dose must be obtained directly from the healthcare professional who is managing the administration of the medicine. The decision on how to proceed is a clinical one based on the individual treatment schedule.


Q: Can I drink coffee while taking Amikozit?

Regulatory information does not list coffee or caffeine as a specific substance that strongly interacts with Amikozit. While official labels do not strictly prohibit coffee, it is generally recommended to use caution with substances that can worsen side effects such as dizziness or stomach discomfort, as these effects may be additive with antibiotic use.


Q: Are there any long-term effects of taking Amikozit that people worry about?

The primary safety concerns noted in regulatory warnings, especially when therapy is prolonged beyond the standard 7 to 10 days, are the risk of severe and potentially permanent damage to hearing and balance (ototoxicity) and kidney damage (nephrotoxicity). These potential effects emphasize the critical nature of the strict treatment duration and the mandatory monitoring protocols established for this drug.


Q: Are there any foods I should strictly avoid while on Amikozit?

Since the most common form of Amikozit is administered by injection or infusion and not taken by mouth, official prescribing information does not list any mandatory dietary restrictions or foods that must be strictly avoided during treatment.


Q: Can Amikozit be taken on an empty stomach?

This question does not typically apply, as Amikozit is administered through injection or intravenous infusion. Since the medication bypasses the digestive system and is not taken orally, whether the stomach is full or empty is generally not a factor in its administration.


Q: How long does it take for Amikozit to clear an infection?

The standard treatment course for acute, severe infections is typically set for 7 to 10 days to ensure the complete eradication of the pathogen. While clinical signs usually begin to improve within the first 24 to 48 hours, completing the full duration of treatment is essential to maximize the chances of completely eradicating the infection.


Q: Is there a possibility of becoming dependent on Amikozit?

Official regulatory documents do not classify Amikozit as a controlled substance, and the product information does not include any warnings or indications of a potential for physical dependence or abuse associated with its short-term therapeutic use as an antibiotic.


Q: Does Amikozit interact with alcohol, and how severe is the interaction?

Official drug labels do not list a major specific interaction between Amikozit and alcohol. While official drug labels do not list a major specific interaction, consumption of alcohol may potentially worsen some of the common side effects of antibiotics, such as dizziness or stomach upset.


Q: Are there common signs that Amikozit is starting to work?

Studies and official information indicate that common signs of the drug beginning to work include improvement in the patient’s condition, such as a drop in fever, reduced white blood cell count, or a decrease in the overall symptoms related to the infection being treated.

How should Amikozit be stored and disposed of?

Official Storage and Handling Requirements

The required storage conditions for Amikozit (Amikacin) differ based on the product formulation. The Amikacin Injection Solution must be stored at Controlled Room Temperature (20^circ to 25 C) and protected from freezing. It must be dispensed in a tight, light-resistant container. Once opened or diluted, the injection solution must be used immediately and not stored.

Amikacin Liposome Inhalation Suspension must be stored refrigerated (2^circ to 8 C) and kept in its original carton to protect from light. This formulation must also be protected from freezing. If the vials are removed from refrigeration, they can be stored at room temperature for a single period of up to four weeks, after which any unused medicine must be discarded.

Disposal of Amikozit

All unused medicinal product, expired medicine, and waste material must be disposed of in accordance with local requirements for pharmaceutical waste. This ensures proper environmental handling and management.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Amikozit found in:

A-Z Index: